failure
Alnylam’s shares plunge by 42% after deaths in clinical trials
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran
Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again
August 9, 2016Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure
AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …
Chiasma cuts staff by 33% after FDA rejects rare disease drug, Mycapssa
June 16, 2016Research and Development, Sales and Marketing FDA, chiasma, cutbacks, failure, workforce cuts
US-based biopharmaceutical company, Chiasma (NASDAQ: CHMA), has announced substantial job cuts as it attempts to restructure following the US Food …
Biomarin withdraws regulatory submissions for Duchenne muscular dystrophy drug
June 1, 2016Research and Development, Sales and Marketing BioMarin, Duchenne Muscular Dystrophy, EMA, FDA, Kyndrisa, failure, rejection
Biomarin (NASDAQ: BMRN) has announced that it has withdrawn its marketing authorisation application for Duchenne muscular dystrophy drug, Kyndrisa (drisapersen), …
Almost 9 in 10 CCGs not implementing NICE guidelines on antibiotic resistance
May 12, 2016Research and Development, Sales and Marketing CCGs, NICE, antibiotic resistance, failure
The Patients Association has called on all Clinical Commissioning Groups (CCGs) to implement the National Institute for Health and Care …
Clovis cuts staff by 35% after FDA knock back on lung cancer drug
May 6, 2016Manufacturing and Production, Research and Development, Sales and Marketing FDA, Q1 results, clovis, failure, job cuts, job losses, rociletinib, workforce
Clovis Oncology (NASDAQ: CLVS) is set to cut up to 35% of its workforce following the US Food and Drug …
HIV successfully overcomes CRISPR gene-editing technology
April 8, 2016Research and Development HIV, crispr, failure, setback
Researchers using the CRISPR gene-editing technology have indicated that HIV can defeat efforts to cripple it, but have characterised it …
Novartis heart drug sees stellar results
September 1, 2014Sales and Marketing Diovan, LCZ696, Novartis, failure, heart, valsartan
Novartis’ new heart pill has produced stellar results in helping patients with heart failure live longer, making it the first …
Torisel-Avastin combo fails in kidney cancer
August 13, 2012Research and Development, Sales and Marketing R&D, Sutent, Torisel, avastin, failure, rcc
Combining Pfizer’s Torisel and Roche’s Avastin does not increase survival rates for advanced kidney cancer patients. This is according to …
Erbitux fails in gastric cancer trial
July 6, 2012Research and Development, Sales and Marketing Erbitux, Merck Serono, Roche, failure, gastric cancer
Merck’s Erbitux has failed to increase survival in patients with gastric cancer, representing a blow to the firm’s ambition to …
AstraZeneca pulls depression drug, takes $50m hit
March 20, 2012Research and Development, Sales and Marketing AstraZeneca, R&D, depression, failure, pipeline
AstraZeneca and partner Targacept will not file their depression drug TC-5214 for regulatory review. The decision comes after disappointing Phase …
Latest content
